AlzeCure Pharma AB
Share:
Subscribe:

Martin Jönsson CEO o Johan Sandin CSO AlzeCure Pharma

Wed, Oct 06, 2021 08:00 CET

Medium resolution

Original resolution

Subscribe

Related Releases

New data showing the potential of the NeuroRestore project in depression presented at ECNP 2021 conference Tue, Oct 05, 2021 10:00 CET

AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses Fri, Aug 27, 2021 08:00 CET